Mangoceuticals (MGRX) announced that the Company received a letter on October 30, 2024 from The Nasdaq Stock Market indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGRX:
- Mangoceuticals board initiates process to evaluate strategic alternatives
- Mangoceuticals Defends Against Eli Lilly Allegations
- Mangoceuticals ‘refutes’ claims by Eli Lilly regarding sale of tirzepatide
- Mangoceuticals Inc trading halted, news pending
- Mangoceuticals announces 1-for-15 reverse stock split